文献速递腹部介入MR

基线容积多参数MRI能否预测接受经导管动脉化疗栓塞的不可切除肝内胆管癌患者的生存

Baseline Volumetric Multiparametric MRI: Can It Be Used to Predict Survival in Patients with Unresectable Intrahepatic Cholangiocarcinoma Undergoing Transcatheter Arterial Chemoembolization?
PubMed 文献 · Radiology · 2018-08-21

本回顾性研究纳入111例不可切除肝内胆管癌患者,分析基线MRI容积多参数(ADC、存活肿瘤体积百分比、存活肿瘤负荷)与TACE后生存的关系。基线ADC≤1415×10⁻⁶ mm²/sec、存活肿瘤体积百分比>90%与更高生存相关,多参数MRI风险分层可区分生存期。

要点

  • 基线ADC≤1415×10⁻⁶ mm²/sec者总生存优于>1415×10⁻⁶ mm²/sec者(P=.005;总生存第25百分位17个月 vs 7个月)。
  • 存活肿瘤体积百分比>90%者总生存优于≤90%者(P=.001;总生存第25百分位20个月 vs 7个月)。
  • 多参数MRI风险分层低危 vs 中危 vs 高危的总生存第25百分位分别为22个月 vs 10个月 vs 7个月(P=.002)。

核心结论

  • 基线多参数MRI评估包括容积ADC、存活肿瘤体积百分比和存活肿瘤负荷,可能有助于预测接受TACE的肝内胆管癌患者的死亡风险。

研究设计与样本

  • 回顾性研究,符合HIPAA并获机构审查委员会批准,豁免知情同意。
  • 纳入111例患者(平均年龄62岁±12;范围29-86岁),其中男性44例(平均年龄61岁±12;范围29-81岁),女性67例(平均年龄63岁±12;范围34-86岁)。
  • 患者于2003年至2016年间在基线MRI后接受TACE,MRI包括增强扫描和扩散加权成像及ADC图。
  • 由一名放射科医师独立评估单个最大肿瘤的解剖和功能参数(存活肿瘤体积、存活肿瘤体积百分比[100×存活肿瘤体积/整个肿瘤体积]、存活肿瘤负荷[100×存活肿瘤体积/全肝体积]和ADC)。
  • 采用Kaplan-Meier和Cox回归进行生存分析。

诊断标准与关键数值

  • 基线ADC≤1415×10⁻⁶ mm²/sec vs >1415×10⁻⁶ mm²/sec:总生存更高(P=.005;总生存第25百分位17个月 vs 7个月)。
  • 存活肿瘤体积百分比>90% vs ≤90%:总生存更高(P=.001;总生存第25百分位20个月 vs 7个月)。
  • 存活肿瘤负荷>6.6% vs ≤6.6%:总生存第25百分位17个月 vs 7个月(P=.09)。
  • 基线ADC>1415×10⁻⁶ mm²/sec(HR:2.176 [95%CI:1.217, 3.891];P=.009)和存活肿瘤体积百分比>90%(HR:0.319 [95%CI:0.148, 0.685];P=.003)与总生存相关,独立于临床混杂因素(年龄和性别)。
  • 多参数MRI风险分层(低ADC和高存活肿瘤体积百分比视为生存有利):低危 vs 中危 vs 高危的总生存第25百分位分别为22个月 vs 10个月 vs 7个月(P=.002)。

临床应用与阅片要点

  • 原文结论指出基线多参数MRI评估可能有助于预测接受TACE的肝内胆管癌患者的死亡风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To evaluate whether baseline MRI can help predict survival in patients with unresectable intrahepatic cholangiocarcinoma (ICCA) undergoing transcatheter arterial chemoembolization (TACE). Materials and Methods This retrospective study was compliant with HIPAA and approved by the institutional review board. The requirement to obtain informed consent was waived. The study included 111 patients (mean age, 62 years ± 12; range, 29-86 years), with 44 men (mean age, 61 years ± 12; range, 29-81 years) and 67 women (mean age, 63 years ± 12; range, 34-86 years). Patients underwent TACE after baseline MRI, which included contrast-enhanced and diffusion-weighted imaging with apparent diffusion coefficient (ADC) mapping between 2003 and 2016. The single largest tumor was assessed independently by a radiologist for anatomic and functional (viable tumor volume, percentage viable tumor volume [100 × viable tumor volume/whole tumor volume], viable tumor burden [100 × viable tumor volume/whole liver volume], and ADC) parameters. Survival analysis was performed with Kaplan-Meier and Cox regression analysis. Results Overall survival (OS) was higher with a baseline ADC of 1415 × 10-6 mm2/sec or less compared with greater than 1415 × 10-6 mm2/sec (P = .005; 25th percentile of OS, 17 months vs 7 months, respectively), percentage viable tumor volume greater than 90% compared with 90% or less (P = .001; 25th percentile of OS, 20 months vs 7 months, respectively), and viable tumor burden greater than 6.6% compared with 6.6% or less (P = .09; 25th percentile of OS, 17 months vs 7 months, respectively). Baseline ADC greater than 1415 × 10-6 mm2/sec (hazard ratio [HR]: 2.176 [95% confidence interval: 1.217, 3.891]; P = .009) and percentage viable tumor volume greater than 90% (HR: 0.319 [95% confidence interval: 0.148, 0.685]; P = .003) were associated with OS independent of clinical confounders (age and sex). At multiparametric MRI risk stratification (with low ADC and high percentage viable tumor volume considered favorable for survival), differences in OS were noted (P = .002; 25th percentile of OS for low vs intermediate vs high risk, 22 months vs 10 months vs 7 months, respectively). Conclusion Baseline multiparametric MRI assessment including volumetric ADC, percentage viable tumor volume, and viable tumor burden can help predict mortality risk among patients with intrahepatic cholangiocarcinoma undergoing transcatheter arterial chemoembolization. © RSNA, 2018 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Pandey A, Pandey P, Ghasabeh MA, et al. Baseline Volumetric Multiparametric MRI: Can It Be Used to Predict Survival in Patients with Unresectable Intrahepatic Cholangiocarcinoma Undergoing Transcatheter Arterial Chemoembolization? Radiology. 2018. PMID: 30129899. doi:10.1148/radiol.2018180450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。